Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955126 | 0.90 | MEN1 (0.49) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL11206457 | 0.90 | MEN1 (0.45) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL3241355 | 0.83 | MEN1 (0.51) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL2570533 | 0.83 | MEN1 (0.39) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL10814271 | 0.83 | MEN1 (0.52) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL6839422 | 0.81 | MEN1 (0.56) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL2576527 | 0.81 | MEN1 (0.66) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL31273672 | 0.81 | KDM4E (0.39) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL10816275 | 0.80 | MEN1 (0.47) | MEN1KMT2ATSHRLMNASMN1; SMN2 | |
| SCHEMBL27041175 | 0.79 | HPRT1 (0.40) | MEN1KMT2ATSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2011133876-A2 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | NSUN2, BCDIN3D, ADAR | MEN1 2256/4885KMT2A 3068/4885TSHR 4445/4885 |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ADAR, TYMS, POLM | MEN1 2296/4885KMT2A 3042/4885TSHR 3798/4885 |
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | NSUN2, BCDIN3D, RNGTT | MEN1 2563/4885KMT2A 3169/4885TSHR 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.